Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

NCT05577442 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasm Female

Interventions

DRUG: Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy

Sponsor

Peking University Cancer Hospital & Institute